BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 33389654)

  • 21. CNS-directed therapy in young children with T-lineage acute lymphoblastic leukemia: High-dose methotrexate versus cranial irradiation.
    Nathan PC; Maze R; Spiegler B; Greenberg ML; Weitzman S; Hitzler JK
    Pediatr Blood Cancer; 2004 Jan; 42(1):24-9. PubMed ID: 14752790
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral mucositis in children with acute lymphoblastic leukemia after high-dose methotrexate treatment without delayed elimination of methotrexate: relation to pharmacokinetic parameters of methotrexate.
    Rask C; Albertioni F; Schrøder H; Peterson C
    Pediatr Hematol Oncol; 1996; 13(4):359-67. PubMed ID: 8837142
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Study on elimination delay in high dose methotrexate therapy in childhood acute lymphoblastic leukemia].
    Xu WQ; Tang YM; Fang CQ; Song H; Shi SW; Yang SL; Ren DT; Shen HQ; Qian BQ
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):15-8. PubMed ID: 15946502
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-dose methotrexate therapy (6-8 g/m2) in childhood malignancies: clinical tolerability and pharmacokinetics.
    Slørdal L; Kolmannskog S; Moe PJ; Prytz PS; Aarbakke J
    Pediatr Hematol Oncol; 1987; 4(1):33-42. PubMed ID: 3152911
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of a microRNA binding site polymorphism in SLC19A1 on methotrexate concentrations in Chinese children with acute lymphoblastic leukemia.
    Wang SM; Sun LL; Zeng WX; Wu WS; Zhang GL
    Med Oncol; 2014 Jul; 31(7):62. PubMed ID: 24927955
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia.
    Skärby TV; Anderson H; Heldrup J; Kanerva JA; Seidel H; Schmiegelow K;
    Leukemia; 2006 Nov; 20(11):1955-62. PubMed ID: 16990760
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Calcium Channel Blockers Possibly Delay the Elimination of Plasma Methotrexate in Patients Receiving High-Dose Methotrexate Therapy.
    Inose R; Takahashi K; Nanno S; Hino M; Nagayama K
    J Chemother; 2019 Feb; 31(1):30-34. PubMed ID: 30773130
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile.
    Sorich MJ; Pottier N; Pei D; Yang W; Kager L; Stocco G; Cheng C; Panetta JC; Pui CH; Relling MV; Cheok MH; Evans WE
    PLoS Med; 2008 Apr; 5(4):e83. PubMed ID: 18416598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of pre-hydration and pharmacogenetics on plasma methotrexate concentration and renal dysfunction following high-dose methotrexate therapy.
    Yanagimachi M; Goto H; Kaneko T; Naruto T; Sasaki K; Takeuchi M; Tanoshima R; Kato H; Yokosuka T; Kajiwara R; Fujii H; Tanaka F; Goto S; Takahashi H; Mori M; Kai S; Yokota S
    Int J Hematol; 2013 Dec; 98(6):702-7. PubMed ID: 24241962
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of methotrexate elimination after high dose infusion in children with acute lymphoblastic leukaemia using a population pharmacokinetic approach.
    Odoul F; Le Guellec C; Lamagnère JP; Breilh D; Saux MC; Paintaud G; Autret-Leca E
    Fundam Clin Pharmacol; 1999; 13(5):595-604. PubMed ID: 10520733
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of plasma methotrexate level and MTHFR genotype in Korean paediatric patients with acute lymphoblastic leukaemia.
    Chae H; Kim M; Choi SH; Kim SK; Lee JW; Chung NG; Cho B; Kim Y
    J Chemother; 2020 Sep; 32(5):251-259. PubMed ID: 32431230
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Previously Unknown Drug-Drug Interaction Is Suspected in Delayed Elimination of Plasma Methotrexate in High-Dose Methotrexate Therapy.
    Ishizaki J; Nakano C; Kitagawa K; Suga Y; Sai Y
    Ann Pharmacother; 2020 Jan; 54(1):29-35. PubMed ID: 31416331
    [No Abstract]   [Full Text] [Related]  

  • 33. Population pharmacokinetics of methotrexate in paediatric patients with acute lymphoblastic leukaemia and malignant lymphoma.
    Zhan M; Sun Y; Zhou F; Wang H; Chen Z; Yan L; Li X
    Xenobiotica; 2022 Mar; 52(3):265-273. PubMed ID: 35446233
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma homocysteine, methionine and S-adenosylhomocysteine levels following high-dose methotrexate treatment in pediatric patients with acute lymphoblastic leukemia or Burkitt lymphoma: association with hepatotoxicity.
    Kubota M; Nakata R; Adachi S; Watanabe K; Heike T; Takeshita Y; Shima M
    Leuk Lymphoma; 2014 Jul; 55(7):1591-5. PubMed ID: 24090503
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Standardized Supportive Care Documentation Improves Safety of High-Dose Methotrexate Treatment.
    Alsdorf WH; Karagiannis P; Langebrake C; Bokemeyer C; Frenzel C
    Oncologist; 2021 Feb; 26(2):e327-e332. PubMed ID: 33215763
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of HD-MTX in infants, children, and adolescents with non-B acute lymphoblastic leukemia.
    Donelli MG; Zucchetti M; Robatto A; Perlangeli V; D'Incalci M; Masera G; Rossi MR
    Med Pediatr Oncol; 1995 Mar; 24(3):154-9. PubMed ID: 7838036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study.
    Mahoney DH; Shuster JJ; Nitschke R; Lauer S; Steuber CP; Camitta B
    J Clin Oncol; 2000 Mar; 18(6):1285-94. PubMed ID: 10715299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
    Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
    J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predicting delayed methotrexate elimination in pediatric acute lymphoblastic leukemia patients: an innovative web-based machine learning tool developed through a multicenter, retrospective analysis.
    Jian C; Chen S; Wang Z; Zhou Y; Zhang Y; Li Z; Jian J; Wang T; Xiang T; Wang X; Jia Y; Wang H; Gong J
    BMC Med Inform Decis Mak; 2023 Aug; 23(1):148. PubMed ID: 37537590
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ethnic-specific predictors of neurotoxicity among patients with pediatric acute lymphoblastic leukemia after high-dose methotrexate.
    Harris RD; Bernhardt MB; Zobeck MC; Taylor OA; Gramatges MM; Schafer ES; Lupo PJ; Rabin KR; Scheurer ME; Brown AL
    Cancer; 2023 Apr; 129(8):1287-1294. PubMed ID: 36692972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.